An Extended Dosing, Two-Phase Study of MDX-010 [ipilimumab] as Monotherapy or in Combination With Tyrosinase/gp100/MART-1 Peptides Emulsified With Montanide ISA 51 VG [melanoma vaccine] in the Treatment of Subjects With Resected Stage III or Stage IV Melanoma

Trial Profile

An Extended Dosing, Two-Phase Study of MDX-010 [ipilimumab] as Monotherapy or in Combination With Tyrosinase/gp100/MART-1 Peptides Emulsified With Montanide ISA 51 VG [melanoma vaccine] in the Treatment of Subjects With Resected Stage III or Stage IV Melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2010

At a glance

  • Drugs Ipilimumab; Melanoma vaccine
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Apr 2010 'Bristol-Myers Squibb' added as trial affiliate and sponsor as reported by ClinicalTrials.gov.
    • 13 Apr 2010 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
    • 13 Apr 2010 Actual patient number (75) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top